Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sevelamer Carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives Approval from U.S. FDA for Sevelamer Carbonate for Oral Suspension
Details : Lupin received approval from the USFDA for its Abbreviated New Drug Application Sevelamer Carbonate for Oral Suspension, which is a generic equivalent of Renvela® for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme, used to treat increased phosphate...
Brand Name : Sevelamer Carbonate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 25, 2021
Lead Product(s) : Sevelamer Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sevelamer Carbonate
Therapeutic Area : Nephrology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives Approval for Sevelamer Carbonate Tablets
Details : Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.
Brand Name : Sevelamer Carbonate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 25, 2021
Lead Product(s) : Sevelamer Carbonate
Therapeutic Area : Nephrology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?